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Abstract
Background: Depression is prevalent in people with type 2 diabetes and affects both glycaemic
control and overall quality of life. The aim of this investigator-initiated trial was to evaluate the
effect of the antidepressant paroxetine on quality of life, metabolic control, and mental well-being
in mildly depressed diabetics aged 50–70 years.
Methods: We randomised 49 mildly depressed primary care outpatients with non-optimally
controlled diabetes to a 6-month double-blind treatment with either paroxetine 20 mg per day or
matching placebo. Primary efficacy measurements were quality of life and glycaemic control. The
primary global outcome of the study was defined as a 10 points improvement in the SF-36 quality
of life score. The primary metabolic outcome of the study was defined as a 0.8%-units decrease in
glycosylated haemoglobin A1c(GHbA1c). Psychiatric symptoms were assessed with the Hospital
Anxiety and Depression Scale.
Results: Six patients withdrew their consent before starting medication and six dropped out later
in the study. We performed analysis of covariance with the baseline value as a covariate. Quality of
life and glycaemic control as well as symptoms of depression and anxiety improved in both groups
over the 6-month study period. After three months of treatment we found a statistically significant
difference between the two treatment groups in GHbA1c (mean difference = 0.59%-units, p =
0.018) and in SF-36 score (mean difference = 11.0 points, p = 0.039). However, at the end of the
study, no statistically significant differences between the treatment groups were observed. No
severe adverse events occurred.
Conclusion: This pragmatic study of primary care patients did not confirm earlier preliminary
findings indicating a beneficial effect of paroxetine on glycaemic control. The study indicates that in
pragmatic circumstances any possible benefit from administration of paroxetine in diabetic patients
with sub-threshold depression is likely to be modest and of short duration. Routine antidepressant
prescription for patients with diabetes and sub-threshold depressive symptoms is not indicated.
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Background
Type 2 diabetes, characterised by both insulin resistance
and impaired insulin secretion, is a common disease with
rapidly increasing prevalence worldwide [1,2]. Insulin
resistance is one of the primary metabolic defects, both in
the metabolic syndrome and in manifest type 2 diabetes.
Therefore a main treatment target is to improve insulin
sensitivity. The cornerstones of treatment are non-phar-
macological i.e. exercise and improved dietary habits.
Both weight loss and physical activity are known to
improve insulin sensitivity [3]. Unfortunately, success of
non-pharmacologic treatment is rare. Therefore other
means to improve glycaemic control are urgently needed.
Depression is common among diabetics [4] and it has
indeed been suggested that one possibility for pharmaco-
logical treatment of insulin resistance is the use of antide-
pressive agents such as the selective serotonin reuptake
inhibitors (SSRIs). It has previously been shown that the
SSRI fluoxetine lowers blood glucose levels in type 2 dia-
betics [5,6]. Fluoxetine has also been shown to promote
weight loss [7], which in itself would improve insulin sen-
sitivity. Interestingly, this effect of fluoxetine on insulin
sensitivity also occurs independently of weight loss [8].
The mechanism behind this effect is not known.
The metabolic syndrome is characterised not only by insu-
lin resistance but also by obesity, elevated blood pressure,
dyslipidemia, and an increased risk for cardiovascular dis-
ease. Symptoms of depression among type 2 diabetics
have been shown to correlate with glycaemic control
although it is not clear whether this is due primarily to
non-compliance with the anti-diabetic medication or to
depression [9]. Therefore, in order to reduce the risk for
cardiovascular diseases associated with the metabolic syn-
drome and type 2 diabetes, it is important to treat not
only the metabolic derangements in type 2 diabetes but
all risk factors accompanying the disease. It is of interest
to see whether antidepressant drug therapy could prove
beneficial for diabetics with regard to metabolic control as
well as mental health.
The use of antidepressant medication has increased dra-
matically in many countries since the introduction of
SSRIs [10]. A majority of prescriptions is done by general
practitioners in primary care and many primary care
patients have sub-threshold or mild depression [11].
We performed a small-scale single-blind paroxetine pilot
study [12], and found that paroxetine had a beneficial
effect on measures of insulin sensitivity. This motivated a
further, longer and methodologically less biased study.
The aim of our current study was to assess whether the
SSRI paroxetine has beneficial effects on quality of life and
overall metabolic control in a generalisable primary care
sample of type 2 diabetics in the age range 50–70 years.
Methods
Mildly depressed type 2 diabetes out-patients were invited
to participate in this investigator-initiated 6-month trial.
All subjects received standard diabetes treatment by their
primary care physicians prior to and during the trial. Men
and women between 50 and 70 years of age, who had
been diagnosed with type 2 diabetes at least a year prior to
study entry, were eligible for the study. They had to be on
stable hypoglycaemic medication for at least three
months before entering the study.
The inclusion criteria included non-optimal glycaemic
control – defined as glycosylated haemoglobin A1c
(GHbA1c) > 7.0 % – and mild depression, i.e. not more
than six depressive symptoms according to Diagnostic
and Statistical Manual of Mental Disorders, 4th edition,
(DSM-IV) criteria [13]. The participants were interviewed
by one of the authors (M.P) who was trained to perform a
psychiatric interview. Their mood and anxiety levels were
evaluated using the clinician-rated Hospital Anxiety and
Depression Scale (HADS) [14] and quality of life was
assessed with the SF-36 questionnaire [15].
Subjects with a moderate to severe depression based on
DSM-IV criteria were excluded as we considered it unethi-
cal to include more severely depressed patients because of
the possibility of receiving placebo. Subjects were
excluded if they had glaucoma [16] and if they were using
warfarin [17] because of possible adverse effects of parox-
etine in these conditions. Furthermore, subjects with
major complications due to diabetes (e.g. major cardio-
vascular, renal or vascular disease, and blindness) and
subjects who used any kind of antidepressants were also
excluded.
Our primary outcomes were improvement of GHbA1c and
the SF-36 quality of life score. A mean difference between
the treatment groups of 0.8 %-units in GHbA1c was con-
sidered to be clinically significant and power calculation,
assuming an alpha error of 5 % and a beta error of 20 %,
indicated that 19 patients per group were required to evi-
dence this difference. Allowing for a drop-out rate of 20
%, 50 patients were to be included in the study.
The randomisation was computerised and concealed to
participants, investigators and treating physicians. The
identical tablets were packed in identical vials by the hos-
pital pharmacy according to the randomisation schedule.
The allocation remained concealed throughout the trial.
The investigators did not take part in the clinical treatment
of the study participants.BMC Family Practice 2007, 8:34 http://www.biomedcentral.com/1471-2296/8/34
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At baseline and after 3 and 6 months the quality of life
and mental status of the participants were evaluated using
SF-36 and HADS. Body mass index (kg/m2) was calcu-
lated using body weight measured to the nearest kg and
height to the nearest cm. At the same time points blood
samples were drawn for the following analyses: serum glu-
cose, GHbA1c, serum C-peptide and serum sex hormone
binding globulin (SHBG). All measurements were made
after an overnight fast.
At baseline, at 1, 3 and 6 months adverse events were reg-
istered and the following safety blood tests were taken:
blood count, serum sodium, serum potassium and liver
enzymes. Subjects were to be removed from the study if
any safety tests showed abnormal results. We ensured
compliance with the medication by counting the left over
pills at each visit.
The study was approved by the Ethics Committee of Hel-
sinki University Central Hospital. All participants signed
an informed consent form and were not reimbursed for
participating in the study.
Differences between the two treatment groups were
assessed with analysis of covariance (ANCOVA), where
baseline measurements were used as covariates. Changes
from baseline were calculated with a paired samples t-test.
Kolmogorov-Smirnov-test was used to test for normality
of the data. All analyses were made with the SPSS 13.0
software.
Results
Seventy-two diabetic patients were interviewed in person
and 23 of these did not meet the inclusion criteria for the
study. The most common reason for exclusion was good
glycaemic control indicated by a GHbA1c-value of 7.0 %
or lower (n = 15). The remaining 49 subjects were ran-
domly assigned to take either placebo (n = 25) or 20 mg
paroxetine (n = 24) once a day in a double-blind fashion.
Six subjects withdrew their consent before starting medi-
cation. Six participants dropped out later in the study,
notably all of them allocated to the placebo group (Figure
1). Two subjects dropped out due to lack of positive sen-
sations from the treatment. Other reasons for aborting
were initiation of insulin treatment (n = 2), erectile dys-
function (n = 1) and hospitalisation due to cardiac event
(n = 1).
Baseline characteristics of those 33 men and 10 women
who entered the trial and received medication are given in
Table 1. The two groups had similar baseline features and
Table 1: Baseline characteristics of mildly depressed patients with type 2 diabetes who entered treatment.
Placebo (n = 20) Paroxetine (n = 23)
Mean SD Mean SD
Sex (M/F) 16/4 17/6
Age (years) 59.5 6.0 59.2 5.4
Body mass index (kg/m2) 32.0 5.3 31.7 5.5
Metabolic parameters
GHbA1c (%) 8.7 1.3 8.5 0.9
Fasting serum glucose (mmol/l) 10.4 3.4 10.4 3.7
Serum C-Peptide (nmol/l) 0.69 0.53 0.74 0.91
Sex hormone binding globulin (nmol/l) 43.2 23.1 37.0 18.7
Mental status
Hospital Anxiety and Depression Scale total score 15.7 5.5 14.0 5.2
Hospital Anxiety and Depression Scale depression score 8.4 3.4 7.3 3.4
Hospital Anxiety and Depression Scale anxiety score 7.3 3.0 6.7 2.6
SF-36 composite score 48.5 15.7 56.2 17.4
Flow chart of trial participants Figure 1
Flow chart of trial participants.
eligible and consenting 
(n=49) 
randomised to 
paroxetine (n=24) 
randomised to 
placebo (n=25) 
received paroxetine 
(n=23) 
received placebo 
(n=20) 
analysed at three 
months (n=15) 
analysed at three 
months (n=23) 
completed the 6-
month trial (n=14) 
completed the 6-
month trial (n=23) BMC Family Practice 2007, 8:34 http://www.biomedcentral.com/1471-2296/8/34
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were representative of identified primary care diabetes
patients. The subjects were in general obese with a non-
optimal glycaemic control having mean fasting serum glu-
cose > 8 mmol/l. All patients were on antidiabetic medi-
cation. Seven of the 43 participants received insulin
treatment only and 17 used a combination of insulin and
oral hypoglycaemic agents.
Baseline HADS scores indicated presence of mild depres-
sive and anxiety symptoms. Ten (5 in the paroxetine
group and 5 in the placebo group) of the 43 participants
who started medication fulfilled DSM-IV criteria for a
mild major depressive episode and the remaining 33 (18
in the paroxetine group and 15 in the placebo group) had
sub-threshold depressive symptoms.
After three months there was a statistically significant
improvement in GHbA1c in the paroxetine group (mean
change from baseline = 0.69%-units, p = 0.001) but not in
the placebo group (mean change = 0.11%-units, p = 0.33)
(Figure 2). The difference in mean GHbA1c  between
groups was significant at three months. Controlling for
baseline GHbA1c, HADS, SF-36 or BMI did not influence
the result. At the end of the trial the change from baseline
was no longer significant in the paroxetine group (mean
change = 0.38%-units, p = 0.10) and there was no signifi-
cant difference between groups (Table 2).
A significant improvement in overall quality of life, as
measured by SF-36, was observed in the paroxetine group
(Figure 3). After three months of treatment there was a sta-
tistically significant difference between the two treatment
groups (mean difference = 11.0 points, p = 0.039) (Table
3). This difference remained significant after controlling
for baseline SF-36 score, GHbA1c and BMI. At the end of
the six month trial there was no statistically significant dif-
ference between the two treatment groups in SF-36 score
(Table 3). However, the improvement from baseline was
still statistically significant in the paroxetine group (Figure
3)
Both groups evidenced a decrease of anxiety and depres-
sive symptoms according to the HADS with a trend for a
stronger effect in the paroxetine group. However, no sta-
Mean changes in glycosylated haemoglobin A1c (GHbA1c)  from baseline for type 2 diabetic subjects receiving placebo  or paroxetine Figure 2
Mean changes in glycosylated haemoglobin A1c (GHbA1c) 
from baseline for type 2 diabetic subjects receiving placebo 
or paroxetine. Error bars represent 95% CI:s of means. P-
values for difference between groups are calculated using 
ANCOVA with the baseline value as a covariate.
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Table 2: Means (and 95% CI:s) of metabolic parameters for subjects who completed the study. Mean differences between groups were 
obtained with analyses of covariance with the baseline value as a covariate. Means at three and six months are estimated marginal 
means. GHbA1c = glycosylated haemoglobin A1c.
Placebo (n = 14) Paroxetine (n = 23) Placebo – Paroxetine
Mean (95% CI) Mean (95% CI) Mean difference (95% CI) p
GHbA1c (%)
Baseline 9.0 (8.2 to 9.8) 8.5 (8.0 to 8.9) 0.54 (-0.24 to 1.31) 0.169
3 months 8.5 (8.2 to 8.9) 7.9 (7.6 to 8.2) 0.59 (0.11 to 1.07) 0.018
6 months 8.4 (7.9 to 8.9) 8.3 (7.9 to 8.7) 0.13 (-0.52 to 0.78) 0.693
Serum glucose (mmol/l)
Baseline 10.7 (8.6 to 12.8) 10.4 (8.8 to 12.0) 0.27 (-2.27 to 2.81) 0.829
3 months 10.7 (9.8 to 12.5) 9.7 (8.2 to 11.1) 1.05 (-1.26 to 3.35) 0.362
6 months 10.8 (9.1 to 12.5) 10.2 (8.8 to 11.5) 0.59 (-1.56 to 2.74) 0.580
Serum C-peptide (nmol/l)
Baseline 0.6 (0.3 to 0.8) 0.7 (0.5 to 0.9) -0.15 (-0.46 to 0.15) 0.310
3 months 0.8 (0.6 to 0.9) 0.8 (0.7 to 1.0) -0.04 (-0.25 to 0.16) 0.656
6 months 0.7 (0.6 to 0.9) 0.8 (0.7 to 0.9) -0.04 (-0.21 to 0.14) 0.682
Body mass index (kg/m2)
Baseline 31.1 (29.3 to 34.1) 31.7 (29.8 to 33.1) -0.66 (-4.14 to 2.82) 0.704
3 months 31.1 (30.7 to 31.6) 31.0 (30.6 to 31.3) 0.15 (-0.44 to 0.73) 0.614
6 months 31.4 (30.9 to 31.9) 31.2 (30.8 to 31.6) 0.15 (-0.47 to 0.77) 0.629BMC Family Practice 2007, 8:34 http://www.biomedcentral.com/1471-2296/8/34
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tistically significant difference between paroxetine- and
placebo-treated participants was detected at any time
point (Table 3). There was no significant difference
between the groups regarding body weight or BMI. Nei-
ther was any difference detected in serum glucose, serum
c-peptide or serum SHBG.
A post hoc subgroup analysis of covariance was per-
formed to elucidate whether the response to paroxetine
was stronger among patients who fulfilled DSM-IV criteria
for mild depression. In the subgroup of subjects with five
to six DSM-IV depressive symptoms [n(placebo) = 4,
n(paroxetine) = 5] a significant benefit of paroxetine was
observable in serum glucose levels after six months (mean
difference between groups = 3.88 mmol/l, 95%CI = 0.47
to 7.29, p = 0.032).
Fifteen of the 43 participants who initiated medication
reported adverse events (Table 4). The adverse events were
classified as mild with the exception of the combination
of nausea and hypoglycaemia in one paroxetine-treated
patient, which was classified as a moderate adverse effect.
Discussion
In our study we have shown that paroxetine had a benefi-
cial effect on GHbA1c and quality of life when compared
to placebo after three months of treatment. However,
when treatment was continued the difference between
groups was no longer significant.
Our primary outcomes, which we considered to be clini-
cally significant, were a 0.8%-units difference in GHbA1c
and a 10 points difference in SF-36 when comparing par-
oxetine to placebo. A statistically, significant improve-
ment in SF-36 was reached after three months. However,
by the end of the trial, the effect on quality of life was
somewhat diminished and the difference between groups
was no longer significant.
Our finding of a 0.59%-units difference in GHbA1c is not
clinically significant according to our primary statement.
Moreover even this minor effect was transient. We have no
explanation as to why the effect is not sustained but a sim-
ilar transient effect of fluoxetine on GHbA1c was seen in a
Mean changes in SF-36 quality of life score from baseline for  type 2 diabetic subjects receiving placebo or paroxetine Figure 3
Mean changes in SF-36 quality of life score from baseline for 
type 2 diabetic subjects receiving placebo or paroxetine. 
Error bars represent 95% CI:s of means. P-values for differ-
ence between groups are calculated using ANCOVA with 
the baseline value as a covariate.
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Table 3: Means (and 95% CI:s) of quality of life and mental health rating scores for subjects who completed the study. 
Placebo (n = 14) Paroxetine (n = 23) Placebo-Paroxetine
Mean (95% CI) Mean (95% CI) Mean difference (95% CI) p
SF-36
Baseline 51.2 (42.6 to 59.8) 56.2 (48.6 to 63.7) -4.7 (-16.3 to 6.4) 0.381
3 months 59.1 (51.2 to 67.0) 70.1 (63.4 to 76.7) -11.0 (-21.4 to -0.6) 0.039
6 months 56.9 (47.5 to 66.2) 65.8 (58.5 to 73.6) -8.9 (-20.8 to 2.9) 0.135
HADS total score
Baseline 15.8 (12.5 to 19.1) 14.0 (11.7 to 16.2) 1.8 (-1.9 to 5.6) 0.327
3 months 11.2 (9.0 to 13.5) 8.5 (6.6 to 10.4) 2.8 (-0.2 to 5.7) 0.066
6 months 12.1 (8.9 to 15.4) 10.2 (7.6 to 12.7) 1.9 (-2.2 to 6.1) 0.351
HADS depression score
Baseline 8.2 (6.2 to 10.2) 7.3 (5.8 to 8.7) 0.9 (-1.4 to 3.4) 0.416
3 months 5.1 (3.8 to 6.3) 3.8 (2.7 to 4.9) 1.3 (-0.4 to 2.9) 0.129
6 months 6.2 (4.6 to 7.7) 5.5 (4.3 to 6.6) 0.7 (-1.2 to 2.7) 0.448
HADS anxiety score
Baseline 7.6 (5.8 to 9.4) 6.7 (5.6 to 7.8) 0.9 (-1.1 to 2.8) 0.366
3 months 6.2 (4.8 to 7.6) 4.6 (3.5 to 5.8) 1.6 (-0.2 to 3.4) 0.085
6 months 6.0 (4.0 to 8.0) 4.7 (3.2 to 6.2) 1.3 (-1.2 to 3.8) 0.312
Mean differences between groups were obtained with analyses of covariance with the baseline value as a covariate. Means at three and six months 
are estimated marginal means. HADS = Hospital Anxiety and Depression Scale.BMC Family Practice 2007, 8:34 http://www.biomedcentral.com/1471-2296/8/34
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study by Gray et al [18]. Our post hoc subgroup analysis
suggests that a possible long term effect could be confined
to those who fulfil criteria for clinical depression.
To our knowledge this is the first long-term double-blind
placebo-controlled study where the effects of paroxetine
on quality of life, metabolic control and mental health
have been simultaneously assessed in type 2 diabetic sub-
jects with mild depressive symptoms. According to our
findings patients with sub-threshold depression do not
benefit from a long-term treatment with paroxetine. This
is relevant information for general practitioners who
mostly treat the mildly depressed. It is possible that the
generally used criteria for prescribing SSRIs are to loose
and that GPs should use other methods for treating
patients with sub-threshold depression.
The study was built upon our previous smaller and shorter
single-blind pilot study [12], in which we found a signifi-
cant improvement in an indicator of insulin sensitivity,
SHBG, in the treatment group when compared to the con-
trol group, and a trend towards better glycemic control in
the paroxetine group than in the placebo group. The pre-
vious study had several weaknesses, i.e. small sample size,
(N = 15), lack of double-blindness, short duration (10
weeks), and a rather good baseline metabolic control
(mean GhbA1c 7.5 %). We aimed at overcoming the weak-
nesses of the pilot trial by performing the current 6-month
double-blind trial with stricter inclusion criteria for glya-
cemic control (> 7 % vs. = 6.5 % in the previous trial). We
did not replicate our previous finding of a differential
change in SHBG values in the paroxetine group when
compared to placebo.
Conclusion
Our results do not exclude the possibility that long-term
paroxetine treatment may have an either beneficial or
harmful effect on quality of life or mental health status in
diabetic out-patients with minor depressive symptoms,
but the harmful effect observed in our study was less than
modest and our results indicate that the possible benefi-
cial effect is modest and transient. Routine paroxetine
treatment of diabetics with sub-threshold depression is
not warranted.
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